NASDAQ:XENT - Intersect ENT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $23.00
  • Forecasted Upside: -0.69 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$23.16
▼ -1.05 (-4.34%)
1 month | 3 months | 12 months
Get New Intersect ENT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XENT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XENT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.00
▼ -0.69% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Intersect ENT in the last 3 months. The average price target is $23.00, with a high forecast of $32.00 and a low forecast of $10.00. The average price target represents a -0.69% upside from the last price of $23.16.
Hold
The current consensus among 8 contributing investment analysts is to hold stock in Intersect ENT. This rating has held steady since May 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
11/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
2/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2021Piper SandlerBoost Price TargetNeutral$17.00 ➝ $23.00Medium
i
1/11/2021Canaccord GenuityUpgradeHold ➝ Buy$18.00 ➝ $25.00Low
i
12/3/2020SVB LeerinkBoost Price TargetMarket Perform$18.00 ➝ $22.00High
i
11/19/2020BTIG ResearchUpgradeNeutral ➝ Buy$32.00High
i
11/3/2020SVB LeerinkLower Price TargetMarket Perform$19.50 ➝ $18.00High
i
11/2/2020Piper SandlerBoost Price TargetIn-Line ➝ Neutral$16.00 ➝ $17.00Medium
i
10/22/2020Piper SandlerLower Price TargetNeutral$17.00 ➝ $16.00Medium
i
10/8/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00High
i
8/7/2020GuggenheimUpgradeNeutral ➝ Buy$30.00High
i
8/5/2020SVB LeerinkBoost Price TargetMarket Perform$18.50 ➝ $19.50Medium
i
8/5/2020Canaccord GenuityReiterated RatingHold$18.00High
i
8/4/2020Piper SandlerBoost Price TargetNeutral$14.00 ➝ $17.00High
i
8/4/2020OppenheimerReiterated RatingHoldLow
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
7/15/2020SVB LeerinkBoost Price TargetMarket Perform$14.00 ➝ $18.50Low
i
6/29/2020SVB LeerinkLower Price TargetMarket Perform$15.00 ➝ $14.00High
i
6/23/2020OppenheimerInitiated CoverageMarket PerformHigh
i
6/10/2020BTIG ResearchReiterated RatingHoldHigh
i
5/12/2020SVB LeerinkBoost Price TargetMarket Perform$13.00 ➝ $15.00High
i
5/12/2020JPMorgan Chase & Co.Lower Price TargetOverweight$28.00 ➝ $18.00High
i
5/12/2020Piper SandlerLower Price TargetNeutral$23.00 ➝ $14.00Medium
i
5/12/2020Canaccord GenuityDowngradeBuy ➝ HoldHigh
i
4/15/2020Bank of AmericaDowngradeBuy ➝ Underperform$28.00 ➝ $10.00High
i
4/14/2020SVB LeerinkLower Price TargetMarket Perform$28.00 ➝ $13.00High
i
4/13/2020BTIG ResearchReiterated RatingHoldMedium
i
3/24/2020BTIG ResearchReiterated RatingHoldLow
i
2/25/2020Canaccord GenuityReiterated RatingBuy$30.00High
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$25.00 ➝ $28.00Medium
i
11/1/2019Piper Jaffray CompaniesSet Price TargetHold$21.00N/A
i
Rating by Matthew O'Brien at Piper Jaffray Companies
8/2/2019GuggenheimDowngradeBuy ➝ NeutralHigh
i
8/2/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$30.00 ➝ $17.00High
i
7/10/2019Northland SecuritiesUpgradeUnder Perform ➝ Market Perform$20.00Low
i
6/21/2019Berenberg BankDowngradeBuy ➝ Hold$35.00 ➝ $27.00High
i
5/7/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$41.00 ➝ $29.00High
i
Rating by R. Newitter at SVB Leerink LLC
5/7/2019Northland SecuritiesDowngradeMarket Perform ➝ Under Perform$28.00 ➝ $20.00High
i
2/26/2019BTIG ResearchReiterated RatingHoldHigh
i
2/26/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$36.00 ➝ $40.00Medium
i
11/5/2018Northland SecuritiesReiterated RatingHold$28.00High
i
10/17/2018Northland SecuritiesReiterated RatingHold$28.00Low
i
8/2/2018BTIG ResearchReiterated RatingHoldHigh
i
8/1/2018Canaccord GenuityReiterated RatingBuyHigh
i
8/1/2018Piper Jaffray CompaniesLower Price TargetOverweight$45.00 ➝ $40.00High
i
5/7/2018Canaccord GenuityReiterated RatingBuyLow
i
5/2/2018Northland SecuritiesReiterated RatingHold$32.00Low
i
5/2/2018BTIG ResearchReiterated RatingHoldLow
i
5/2/2018JPMorgan Chase & Co.Reiterated RatingOverweight$48.00Low
i
4/20/2018Berenberg BankInitiated CoverageBuyLow
i
3/1/2018GuggenheimReiterated RatingBuyLow
i
1/2/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
i
12/15/2017GuggenheimReiterated RatingBuy$41.00Low
i
12/11/2017Canaccord GenuityReiterated RatingBuy$36.00Medium
i
11/7/2017BTIG ResearchReiterated RatingHoldN/A
i
11/3/2017Northland SecuritiesReiterated RatingHold$25.00N/A
i
Rating by Suraj Kalia at Northland Securities
9/13/2017Canaccord GenuityBoost Price TargetBuy$32.00 ➝ $37.00Low
i
9/11/2017Bank of AmericaBoost Price TargetBuy$33.00 ➝ $40.00High
i
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00Low
i
8/2/2017Canaccord GenuityReiterated RatingBuy$32.00Medium
i
Rating by Kyle Rose at Canaccord Genuity
8/2/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$27.00 ➝ $31.00High
i
Rating by Brittany Henderson at Deutsche Bank Aktiengesellschaft
8/2/2017Northland SecuritiesReiterated RatingHold$25.00High
i
Rating by Suraj Kalia at Northland Securities
5/31/2017Northland SecuritiesDowngradeOutperform ➝ Market PerformMedium
i
5/10/2017William BlairReiterated RatingOutperformLow
i
Rating by K. Krum at William Blair
5/4/2017Northland SecuritiesBoost Price TargetOutperform$17.00 ➝ $22.00High
i
5/3/2017Canaccord GenuityReiterated RatingBuyHigh
i
Rating by Kyle Rose at Canaccord Genuity
5/3/2017WedbushBoost Price TargetOutperform ➝ Outperform$25.00 ➝ $26.00High
i
3/13/2017Northland SecuritiesReiterated RatingBuy$17.00Low
i
3/8/2017Canaccord GenuityInitiated CoverageBuy$17.00Low
i
Rating by Kyle Rose at Canaccord Genuity
3/6/2017Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$15.00 ➝ $19.00N/A
i
Rating by Brittany Henderson at Deutsche Bank Aktiengesellschaft
2/24/2017WedbushReiterated RatingOutperform$25.00N/A
i
2/21/2017Canaccord GenuityReiterated RatingBuy$16.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
1/23/2017Canaccord GenuitySet Price TargetBuy$16.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
1/11/2017WedbushReiterated RatingOutperform$25.00N/A
i
12/6/2016GuggenheimInitiated CoverageBuy$20.00N/A
i
11/4/2016SVB LeerinkReiterated RatingOutperform$21.00 ➝ $14.00N/A
i
11/2/2016Canaccord GenuitySet Price TargetBuy$20.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
11/2/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $16.00N/A
i
10/18/2016Deutsche Bank AktiengesellschaftSet Price TargetHold$17.00N/A
i
Rating by Brittany Henderson at Deutsche Bank Aktiengesellschaft
10/6/2016Deutsche Bank AktiengesellschaftInitiated CoverageHold$17.00N/A
i
9/23/2016WedbushReiterated RatingOutperform$25.00N/A
i
8/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$21.00N/A
i
8/4/2016Canaccord GenuityReiterated RatingBuy$20.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
8/4/2016BTIG ResearchReiterated RatingHold$14.00N/A
i
Rating by Sean Lavin at BTIG Research
8/3/2016WedbushReiterated RatingOutperform$25.00N/A
i
7/18/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Kyle Rose at Canaccord Genuity
7/18/2016WedbushReiterated RatingOutperform$25.00N/A
i
7/12/2016BTIG ResearchInitiated CoverageNeutralN/A
i
3/29/2016Northland SecuritiesInitiated CoverageOutperform$26.00N/A
i
3/24/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Kyle Rose at Canaccord Genuity
3/24/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Richard Newitter at SVB Leerink LLC
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00N/A
i
(Data available from 2/26/2016 forward)
Intersect ENT logo
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $23.16
$23.16
$24.35

50 Day Range

MA: $24.21
$21.63
$26.62

52 Week Range

Now: $23.16
$5.97
$26.98

Volume

208,526 shs

Average Volume

197,795 shs

Market Capitalization

$757.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Intersect ENT?

The following Wall Street sell-side analysts have issued research reports on Intersect ENT in the last twelve months: Bank of America Co., BTIG Research, Canaccord Genuity, Guggenheim, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, and SVB Leerink LLC.
View the latest analyst ratings for XENT.

What is the current price target for Intersect ENT?

7 Wall Street analysts have set twelve-month price targets for Intersect ENT in the last year. Their average twelve-month price target is $23.00, suggesting a possible downside of 0.7%. BTIG Research has the highest price target set, predicting XENT will reach $32.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $10.00 for Intersect ENT in the next year.
View the latest price targets for XENT.

What is the current consensus analyst rating for Intersect ENT?

Intersect ENT currently has 1 sell rating, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in XENT, but not buy more shares or sell existing shares.
View the latest ratings for XENT.

What other companies compete with Intersect ENT?

How do I contact Intersect ENT's investor relations team?

Intersect ENT's physical mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider's listed phone number is 650-641-2100 and its investor relations email address is [email protected] The official website for Intersect ENT is www.intersectent.com.